Table 2.
Change in PASAT-3” scores from baseline through the placebo-controlled phase and the follow-up phase.
| Placebo-controlled phase | Year 2a | Year 2 (LOCF)b |
|---|---|---|
| IFNβ-1b treatmentc | 2.3± 6.3, 1.0 (0 to 5.00) (n = 191) | 2.0 ± 6.3, 1.0 (–1.0 to 4.0) (n = 273) |
| Placebo treatmentc | 0.8 ± 5.5, 0.5 (–1.0 to 3.0)) (n = 88) | 0.6 ± 5.4, 0.5 (–1.0 to 3.0) (n = 166) |
| p valued | 0.018 | 0.021 |
| Follow-up phase | Year 5 | Year 5 (LOCF) |
| Early treatmentc | 3.4 ± 6.2, 2.0 (0 to 6.0)) (n = 227) | 3.0 ± 6.0, 2.0 (0 to 6.0) (n = 285) |
| Delayed treatmentc | 1.5 ± 6.8, 1.0 (–1.0 to 4.0)) (n = 120) | 1.0 ± 6.5, 1.0 (–1.0 to 4.0) (n = 174) |
| p valued | 0.005 | <0.001 |
a
Includes only those patients who did not progress to CDMS until year 2.
b
Includes patients who progressed to CDMS before year two or prematurely discontinued study.
c
Data are mean ± SD, median (interquartile range).
d
Non-parametric analysis of covariance for change in PASAT-3’’ score from baseline.
IFNβ-1b: interferon beta-1b; LOCF: Last observation carried forward; PASAT-3”: Paced Auditory Serial Addition Test-3”